Literature DB >> 33316306

Glial activation precedes alpha-synuclein pathology in a mouse model of Parkinson's disease.

Maria Izco1, Javier Blesa2, Guglielmo Verona3, J Mark Cooper4, Lydia Alvarez-Erviti5.   

Abstract

Neuroinflammation is increasingly recognized as an important feature in the pathogenesis of Parkinson's disease (PD). However, it remains unclear whether neuroinflammation contributes to nigral degeneration in PD or is merely a secondary marker of neurodegeneration. We aimed to investigate the temporal relationship between synucleopathy, neuroinflammation and nigrostriatal degeneration in a mouse model of PD. Mice received unilateral intrastriatal injection of alpha-synuclein pre-formed fibrils, alpha-synuclein monomer or vehicle and were sacrificed at 15, 30 and 90 days post-injection. Intrastriatal inoculation of alpha-synuclein fibrils led to significant alpha-synuclein aggregation in the substantia nigra peaking at 30 days after injection while the significant increase in Iba-1 cells, GFAP cells and IL-1β expression peaked earlier at 15 days. At 90 days, the striatal dopaminergic denervation was associated with astroglial activation. Alpha-synuclein monomer did not result in long-term glia activation or increase in inflammatory markers. The spread of alpha-synuclein aggregates into the cortex was not associated with any changes to neuroinflammatory markers. Our results demonstrate that in the substantia nigra glial activation is an early event that precedes alpha-synuclein inclusion formation, suggesting neuroinflammation could play an important early role in the pathogenesis of PD.
Copyright © 2020 Elsevier B.V. and Japan Neuroscience Society. All rights reserved.

Entities:  

Keywords:  Alpha-Synuclein; Astrocytes; Microglia; Mouse model; Neuroinflammation; Parkinson’s disease

Mesh:

Substances:

Year:  2020        PMID: 33316306     DOI: 10.1016/j.neures.2020.11.004

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  10 in total

1.  Programmed Death-1 Deficiency Aggravates Motor Dysfunction in MPTP Model of Parkinson's Disease by Inducing Microglial Activation and Neuroinflammation in Mice.

Authors:  Ying-Ying Cheng; Bei-Yu Chen; Gan-Lan Bian; Yin-Xiu Ding; Liang-Wei Chen
Journal:  Mol Neurobiol       Date:  2022-02-10       Impact factor: 5.590

Review 2.  COVID-19 and Parkinson's Disease: Possible Links in Pathology and Therapeutics.

Authors:  Shubhangini Tiwari; Neelam Yadav; Sarika Singh
Journal:  Neurotox Res       Date:  2022-07-13       Impact factor: 3.978

3.  Modulation of Glial Function in Health, Aging, and Neurodegenerative Disease.

Authors:  Kendra L Hanslik; Kaitlyn M Marino; Tyler K Ulland
Journal:  Front Cell Neurosci       Date:  2021-08-31       Impact factor: 5.505

Review 4.  Mechanistic Insight from Preclinical Models of Parkinson's Disease Could Help Redirect Clinical Trial Efforts in GDNF Therapy.

Authors:  Karen M Delgado-Minjares; Daniel Martinez-Fong; Irma A Martínez-Dávila; Cecilia Bañuelos; M E Gutierrez-Castillo; Víctor Manuel Blanco-Alvarez; Maria-Del-Carmen Cardenas-Aguayo; José Luna-Muñoz; Mar Pacheco-Herrero; Luis O Soto-Rojas
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

5.  Evidence of Inflammation in Parkinson's Disease and Its Contribution to Synucleinopathy.

Authors:  Thuy Thi Lai; Yun Joong Kim; Hyeo-Il Ma; Young Eun Kim
Journal:  J Mov Disord       Date:  2021-11-03

6.  Sensitive immunosensing of α-synuclein protein in human plasma samples using gold nanoparticles conjugated with graphene: an innovative immuno-platform towards early stage identification of Parkinson's disease using point of care (POC) analysis.

Authors:  Esmaeil Darvish Aminabad; Ahmad Mobed; Mohammad Hasanzadeh; Mohammad Ali Hosseinpour Feizi; Reza Safaralizadeh; Farzad Seidi
Journal:  RSC Adv       Date:  2022-02-02       Impact factor: 3.361

Review 7.  A Summary of Phenotypes Observed in the In Vivo Rodent Alpha-Synuclein Preformed Fibril Model.

Authors:  Nicole K Polinski
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

8.  PTEN-Induced Putative Kinase 1 Dysfunction Accelerates Synucleinopathy.

Authors:  Tinh Thi Nguyen; Yun Joong Kim; Thuy Thi Lai; Phuong Thi Nguyen; Young Ho Koh; Linh Thi Nhat Nguyen; Hyeo-Il Ma; Young Eun Kim
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

9.  The Intranigral Infusion of Human-Alpha Synuclein Oligomers Induces a Cognitive Impairment in Rats Associated with Changes in Neuronal Firing and Neuroinflammation in the Anterior Cingulate Cortex.

Authors:  Maria Francesca Palmas; Michela Etzi; Augusta Pisanu; Chiara Camoglio; Claudia Sagheddu; Michele Santoni; Maria Francesca Manchinu; Mauro Pala; Giuliana Fusco; Alfonso De Simone; Luca Picci; Giovanna Mulas; Saturnino Spiga; Maria Scherma; Paola Fadda; Marco Pistis; Nicola Simola; Ezio Carboni; Anna R Carta
Journal:  Cells       Date:  2022-08-24       Impact factor: 7.666

Review 10.  Neuroprotection and Disease Modification by Astrocytes and Microglia in Parkinson Disease.

Authors:  Shinichi Takahashi; Kyoko Mashima
Journal:  Antioxidants (Basel)       Date:  2022-01-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.